Case report
Langerhans cell sarcoma emanating from the upper arm skin: successful treatment by MAID regimen

https://doi.org/10.1007/s00776-007-1184-4Get rights and content

References (17)

  • L.M. Weiss et al.

    Langerhans cell sarcoma

  • A. Elias et al.

    Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy

    J Clin Oncol

    (1989)
  • B. Banner et al.

    Interdigitating reticulum-cell sarcoma of the intestine: a case report and review of the literature

    Diagn Cytopathol

    (1997)
  • J. Ben-Ezra et al.

    Malignant histiocytosis X. A distinct clinicopathologic entity

    Cancer

    (1991)
  • M. Al-Abbadi et al.

    Soft tissue Langerhans’ cell histiocytosis in an adult

    A case presentation with flow cytometric analysis and literature review. Arch Pathol Lab Med

    (1997)
  • B.D. Jülg et al.

    Pulmonary manifestation of a Langerhans cell sarcoma: case report and review of the literature

    Virchows Arch

    (2006)
  • H. Itoh et al.

    Primary cutaneous Langerhans cell histiocytosis showing malignant phenotype in an elderly woman: report of a fatal case

    J Cutan Pathol

    (2001)
  • M. Tani et al.

    Malignant Langerhans cell tumour

    Br J Dermatol

    (1992)
There are more references available in the full text version of this article.

Cited by (25)

  • Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States

    2019, Clinical Lymphoma, Myeloma and Leukemia
    Citation Excerpt :

    True epidemiologic data on LCS are lacking; most of our knowledge is obtained from individual case reports.1 As a result of the rarity of the disease, various treatments such as conventional lymphoma therapy protocols using the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen and soft tissue sarcoma regimen (doxorubicin, ifosfamide, and dacarbazine) have been used, with limited success.4,5 We utilized two US national databases—the Surveillance, Epidemiology, and End Results (SEER) Program and the National Cancer Data Base (NCDB)—to study the incidence, clinical presentation, and outcomes of LCS.

  • Langerhans cell sarcoma of the head and neck

    2016, Critical Reviews in Oncology/Hematology
    Citation Excerpt :

    Sixteen studies yielding 17 cases were finally included for the HNLCS cohort (Table 1) (Nakayama et al., 2010; Ben-Ezra et al., 1991; Bohn et al., 2007; Sumida et al., 2008; Yoshimi et al., 2008; Chang et al., 2013; Chung et al., 2013; Keklik et al., 2013; Luo et al., 2011; Muslimani et al., 2012; Park, 2012; Sagransky et al., 2013; Valentín-Nogueras et al., 2013; Wang et al., 2013; Lee et al., 2014; Ma et al., 2014). Thirty-three studies reporting 55 cases of Non-HNLCS were used as a comparison cohort (Pileri et al., 2002; Lee et al., 2006; Ben-Ezra et al., 1991; Chung et al., 2013; Sagransky et al., 2013; Wood et al., 1984; Bonetti et al., 1985; Delabie et al., 1991; Tani et al., 1992; Lauritzen et al., 1994; Itoh et al., 2001; Misery et al., 2003; Diaz-Sarrio et al., 2007; Ferringer et al., 2006; Julg et al., 2006; Kawase et al., 2005; Langfort et al., 2009; Lian et al., 2006; Ratei et al., 2010; Saribeyoglu, 2009; Uchida et al., 2008; Zhao et al., 2009; Yang et al., 2012; Au et al., 2013; Chen et al., 2013; Furmanczyk et al., 2012; Kwong, 2014; Li et al., 2013; Shimizu et al., 2012; Wang et al., 2012; West et al., 2013; Xu et al., 2012; Zwerdling et al., 2014; Jimura et al., 2014; Wang et al., 2015). Within the HN cohort, the male to female ratio was 1.125:1 and the median age at presentation was 56.5 years (inter-quartile range 45–69 years).

  • Langerhans cell sarcoma: A systematic review

    2015, Cancer Treatment Reviews
    Citation Excerpt :

    Their patient showed exceptional response undergoing subsequent bone marrow transplant [7]. The exact regimen has not been repeated however ifosfamide may potentially be efficacious having been used in 5 cases all of whom achieved full remission including 2 cases with 1-site disease [12,50], two with 2-site disease [5,11] and the case by Kwong et al. [7]. Platinum-based therapy has been used in 5 cases with an overall mixed response picture.

  • An unusual pulmonary mass with mediastinal invasion and multiple intrapulmonary nodules in a 52-year-old man

    2012, Chest
    Citation Excerpt :

    After the definite diagnosis was made in this case, we also immediately began systemic chemotherapy with CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, and prednisolone 40 mg/m2); however, he proved to be refractory to the regimen after three courses. Uchida et al12 followed the treatment protocol for soft tissue sarcoma and used a combination of mesna (2,500 mg/m2), doxorubicin (20 mg/m2), ifosfamide (2,500 mg/m2), and dacarbazine (300 mg/m2) (the MAID regimen) for 3 days as neoadjuvant chemotherapy before surgical excision. The response was unexpectedly good, and the patient underwent successful surgical resection resulting in long-term survival.

View all citing articles on Scopus
View full text